Related Experiment Video

Updated: Aug 19, 2026

Longitudinal Follow-Up of Urinary Tract Infections and Their Treatment in Mice using Bioluminescence Imaging
07:39

Longitudinal Follow-Up of Urinary Tract Infections and Their Treatment in Mice using Bioluminescence Imaging

Published on: June 14, 2021

Grepafloxacin

A J Wagstaff1, J A Balfour

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|May 1, 1997
PubMed

Insights

Grepafloxacin, a novel fluoroquinolone antibiotic, shows enhanced activity against Gram-positive bacteria like Streptococcus pneumoniae. Clinical trials confirm its efficacy in treating respiratory and gonococcal infections.

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Fluoroquinolones are broad-spectrum antibiotics with good tissue penetration.
  • There is a need for agents with improved activity against Gram-positive pathogens, such as Streptococcus pneumoniae.

Purpose of the Study:

  • To evaluate the in vitro and in vivo properties of grepafloxacin.
  • To compare the efficacy of grepafloxacin with existing antibiotics in clinical trials.

Main Methods:

  • In vitro antimicrobial susceptibility testing against various bacterial strains.
  • Animal studies to assess safety, including potential for convulsions and phototoxicity.
  • Comparative clinical trials for community-acquired pneumonia, respiratory tract infections, and gonorrhea.

Main Results:

  • Grepafloxacin demonstrated potent activity against Streptococcus pneumoniae, including penicillin-resistant strains, showing 4-fold higher potency than ciprofloxacin.
  • In vitro activity against Enterobacteriaceae was comparable to ciprofloxacin.
  • Animal studies showed no convulsions at high doses with NSAIDs and low phototoxicity potential.
  • Clinical trials indicated grepafloxacin was as effective as amoxicillin, ofloxacin, and cefixime for respective indications.

Conclusions:

  • Grepafloxacin is a promising once-daily fluoroquinolone with broad-spectrum activity and improved Gram-positive efficacy.
  • It is effective and well-tolerated for community-acquired pneumonia, respiratory tract infections, and gonorrhea.
  • Its favorable safety profile and potent activity make it a valuable therapeutic option.

More Related Videos

Time-Lapse Epifluorescence Microscopy Imaging of Pseudomonas aeruginosa and Staphylococcus aureus Heterogeneous Phenotypes07:44

Time-Lapse Epifluorescence Microscopy Imaging of Pseudomonas aeruginosa and Staphylococcus aureus Heterogeneous Phenotypes

Published on: February 14, 2025

Modeling Persistent Pseudomonas aeruginosa Infection in Wounded Zebrafish Larvae06:04

Modeling Persistent Pseudomonas aeruginosa Infection in Wounded Zebrafish Larvae

Published on: June 13, 2025

Related Concept Videos

Antibiotic Selection00:57

Antibiotic Selection

Overview
Acute Pharyngitis01:30

Acute Pharyngitis

Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...